Literature DB >> 29435056

Furin inhibitor D6R suppresses epithelial-mesenchymal transition in SW1990 and PaTu8988 cells via the Hippo-YAP signaling pathway.

Meng Zhou1, Youli Zhang1, Hong Wei1, Junbo He1, Dawei Wang1, Baoding Chen2, Jian Zeng3, Aihua Gong3, Min Xu1.   

Abstract

Hexa-D-arginine (D6R), an inhibitor of furin, has potential therapeutic applications in different types of human tumor. However, the function of D6R in targeting pancreatic cancer cells remains to be elucidated. In the present study, the proliferation, invasion and migration abilities of SW1990 and PaTu8988 cells were examined using a Cell Counting Kit-8, and Transwell and wound healing assays. Subsequently, the expression of proteins associated with epithelial-mesenchymal transition (EMT) and the Hippo-yes-associated protein (YAP) pathway were detected using western blot analysis. It was revealed that D6R significantly inhibited the proliferation, migration and invasion abilities of SW1990 and PaTu8988 cells. Additionally, D6R led to the upregulation of E-cadherin (an epithelial marker), and the downregulation of N-cadherin and vimentin (mesenchymal markers) in SW1990 and PaTu8988 cells. Furthermore, the results of the present study revealed that D6R significantly affected the YAP phosphorylation level and the total YAP protein level, indicating that D6R was functionally involved in the Hippo-YAP signaling pathway. It has been suggested that D6R-suppressed EMT in SW1990 and PaTu8988 cells may occur via the Hippo-YAP pathway and that it may be a feasible drug to ameliorate the malignant phenotype of SW1990 and PaTu8988 cells.

Entities:  

Keywords:  Hippo-yes-associated protein; epithelial-mesenchymal transition; furin; hexa-D-arginine; pancreatic cancer cells

Year:  2017        PMID: 29435056      PMCID: PMC5778862          DOI: 10.3892/ol.2017.7672

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions.

Authors:  A M Khatib; G Siegfried; A Prat; J Luis; M Chrétien; P Metrakos; N G Seidah
Journal:  J Biol Chem       Date:  2001-06-11       Impact factor: 5.157

Review 2.  Recent progress in pancreatic cancer.

Authors:  Christopher L Wolfgang; Joseph M Herman; Daniel A Laheru; Alison P Klein; Michael A Erdek; Elliot K Fishman; Ralph H Hruban
Journal:  CA Cancer J Clin       Date:  2013-07-15       Impact factor: 508.702

3.  Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme.

Authors:  C M Dubois; F Blanchette; M H Laprise; R Leduc; F Grondin; N G Seidah
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

4.  Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor.

Authors:  E Maquoi; A Noël; F Frankenne; H Angliker; G Murphy; J M Foidart
Journal:  FEBS Lett       Date:  1998-03-13       Impact factor: 4.124

5.  Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.

Authors:  Zeshaan A Rasheed; Jie Yang; Qiuju Wang; Jeanne Kowalski; Irwin Freed; Christopher Murter; Seung-Mo Hong; Jan-Bart Koorstra; N V Rajeshkumar; Xiaobing He; Michael Goggins; Christine Iacobuzio-Donahue; David M Berman; Daniel Laheru; Antonio Jimeno; Manuel Hidalgo; Anirban Maitra; William Matsui
Journal:  J Natl Cancer Inst       Date:  2010-02-17       Impact factor: 13.506

6.  Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression.

Authors:  Ricardo López de Cicco; James C Watson; Daniel E Bassi; Samuel Litwin; Andrés J Klein-Szanto
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

7.  Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein.

Authors:  Simona Ozden; Marianne Lucas-Hourani; Pierre-Emmanuel Ceccaldi; Ajoy Basak; Menogh Valentine; Suzanne Benjannet; Josée Hamelin; Yves Jacob; Kamel Mamchaoui; Vincent Mouly; Philippe Desprès; Antoine Gessain; Gillian Butler-Browne; Michel Chrétien; Frédéric Tangy; Pierre-Olivier Vidalain; Nabil G Seidah
Journal:  J Biol Chem       Date:  2008-06-17       Impact factor: 5.157

8.  Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin.

Authors:  H Angliker
Journal:  J Med Chem       Date:  1995-09-29       Impact factor: 7.446

9.  The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo.

Authors:  Miroslav S Sarac; Angus Cameron; Iris Lindberg
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.609

10.  Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target.

Authors:  Rémi Longuespée; Frédéric Couture; Christine Levesque; Anna Kwiatkowska; Roxane Desjardins; Sandra Gagnon; Daniele Vergara; Michelle Maffia; Isabelle Fournier; Michel Salzet; Robert Day
Journal:  Transl Oncol       Date:  2014-05-09       Impact factor: 4.243

View more
  3 in total

Review 1.  Targeting E-cadherin expression with small molecules for digestive cancer treatment.

Authors:  Yizuo Song; Miaomiao Ye; Junhan Zhou; Zhiwei Wang; Xueqiong Zhu
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

2.  Screening for inhibitory effects of crude drugs on furin-like enzymatic activities.

Authors:  Yuka Kiba; Rio Oyama; Sae Misawa; Takashi Tanikawa; Masashi Kitamura; Ryuichiro Suzuki
Journal:  J Nat Med       Date:  2021-04-30       Impact factor: 2.343

Review 3.  Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.

Authors:  Yuan Huang; Chan Yang; Xin-Feng Xu; Wei Xu; Shu-Wen Liu
Journal:  Acta Pharmacol Sin       Date:  2020-08-03       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.